Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 21

Sort by

Sort Order Select

Journal Articles

CM313, a Novel Anti-CD38 Antibody, As a Potential Treatment for Primary Immune Thrombocytopenia: A Phase II Trial

Yunfei Chen, Xu Yanmei, Xuan Cao, Feng Xue, Ting Sun, Wei Liu, Mankai Ju, Rongfeng Fu, Xiaofan Liu, Xinyue Dai, Huiyuan Li, Renchi Yang, Lei Zhang

Blood (2023) 142 (Supplement 1): 1206.

https://doi.org/10.1182/blood-2023-188664

Published: 2023

Journal Articles

Emicizumab Prophylaxis for the Treatment of Chinese Hemophilia A Patients in the Real World: A Multi-Center Retrospective Analysis

Blood (2023) 142 (Supplement 1): 2624.

https://doi.org/10.1182/blood-2023-174698

Published: 2023

Journal Articles

Efficacy and Safety of Human Umbilical Cord-Derived Mesenchymal Stem Cells in the Treatment of Immune Thrombocytopenia: A Prospective, Single Centre, Single Arm, Phase I Trial

Blood (2023) 142 (Supplement 1): 687.

https://doi.org/10.1182/blood-2023-174591

Published: 2023

Journal Articles

Pharmacokinetics, Safety and Preliminary Efficacy of Multiple Doses of Pegylated Recombinant Human Coagulation Factor VIII-Fc Fusion Protein (FRSW117) in Previously Treated Adult and Adolescent Subjects with Severe Hemophilia a: Results from an Open-Label, Multicenter, Phase 2 Study

Feng Xue, Weizhi Chen, Shuxia Guo, Haiying Hua, Yu Cao, Xianqi Feng, Renchi Yang

Blood (2023) 142 (Supplement 1): 2615.

https://doi.org/10.1182/blood-2023-180649

Published: 2023

Journal Articles

Factor XI Deficiency in Chinese Patients: Results from a Nationwide Multicenter Retrospective Study

Xiyan Wang, Feng Xue, Wei Liu, Linging Chen, Lei Zhang, Renchi Yang

Blood (2023) 142 (Supplement 1): 5477.

https://doi.org/10.1182/blood-2023-184688

Published: 2023

Journal Articles

Acquired Hemophilia a: A Single-Center Study of 165 Patients

Dandan Yu, Feng Xue, Xiaofan Liu, Yunfei Chen, Rongfeng Fu, Ting Sun, Xinyue Dai, Mankai Ju, Huan Dong, Renchi Yang, Wei Liu, Lei Zhang

Blood (2023) 142 (Supplement 1): 2623.

https://doi.org/10.1182/blood-2023-173407

Published: 2023

Journal Articles

A Single-Center Study of Patients with Isolated Acquired Clotting Factor Deficiency: Clinical Features, Treatments, and Prognosis

Dandan Yu, Feng Xue, Xiaofan Liu, Yunfei Chen, Rongfeng Fu, Ting Sun, Xinyue Dai, Mankai Ju, Huan Dong, Renchi Yang, Wei Liu, Lei Zhang

Blood (2023) 142 (Supplement 1): 3995.

https://doi.org/10.1182/blood-2023-173431

Published: 2023

Journal Articles

Single-Dose Rituximab Plus Glucocorticoid Versus Cyclophosphamide Plus Glucocorticoid in Patients with Newly Diagnosed Acquired Hemophilia a: A Multicenter, Open-Label, Randomized Clinical Trial

Wei Liu, Rongfu Zhou, Panjing Wang, Hu Zhou, Jie Bai, Xianghua Wang, Yueshen Ma, Zhen Song, Yunfei Chen, Xiaofan Liu, Rongfeng Fu, Ting Sun, Mankai Ju, Xinyue Dai, Huan Dong, Feng Xue, Renchi Yang, Lei Zhang

Blood (2023) 142 (Supplement 1): 2628.

https://doi.org/10.1182/blood-2023-174587

Published: 2023

Journal Articles

A Single-Center Study of Patients with Isolated Acquired Clotting Factors Deficiency: Clinical Features, Treatments and Prognosis

Yu Dandan, Wei Liu, Yunfei Chen, Rongfeng Fu, Liu Xiaofan, Ting Sun, Mankai Ju, Xinyue Dai, Feng Xue, Renchi Yang, Lei Zhang

Blood (2022) 140 (Supplement 1): 11325.

https://doi.org/10.1182/blood-2022-156991

Published: 2022

Journal Articles

Multi-Omics Analysis of Human Mesenchymal Stem Cell Guides Perinatal MSC Based Cellular Therapy for Splenectomy-Nonresponsive Refractory Immune Thrombocytopenia: A Phase I Clinical Trial

Blood (2022) 140 (Supplement 1): 1974–1976.

https://doi.org/10.1182/blood-2022-156764

Published: 2022

Journal Articles

Predictive Factors of Relapse for Primary Immune Thrombocytopenia in Adults: A Single-Center Retrospective Cohort Analysis

Xiyan Wang, Xiaofan Liu, Yueshen Ma, Jiao Wang, Rongfeng Fu, Yunfei Chen, Wei Liu, Ting Sun, Mankai Ju, Hui Yuan Li, Feng Xue, Changping Li, Zhen Song, Lei Zhang, Renchi Yang

Blood (2022) 140 (Supplement 1): 2214–2215.

https://doi.org/10.1182/blood-2022-164457

Published: 2022

Journal Articles

Pharmacokinetics, Efficacy and Safety Evaluation of FRSW107 in Previously Treated Hemophilia a Patients: A Multicentre, Open-Label, Non-Randomized Phase III Study

Blood (2022) 140 (Supplement 1): 8468–8469.

https://doi.org/10.1182/blood-2022-158760

Published: 2022

Journal Articles

AAV8 Gene Therapy for Hemophilia A Patients from China

Wei Liu, Feng Xue, Ting Sun, Bingqi Xu, Xiaolei Pei, Tenghui Yu, Fenglan Wu, Lijun Shen, Renchi Yang, Lei Zhang

Blood (2022) 140 (Supplement 1): 4925.

https://doi.org/10.1182/blood-2022-159363

Published: 2022

Journal Articles

Factor X Activator for Hemophilia Patients with Inhibitors: A Phase 1, First-in-Human, Multi-Center, and Open-Label Trial

Wei Liu, Feng Xue, Rongfeng Fu, Bingjie Ding, Mengjuan Li, Ting Sun, Yunfei Chen, Liu Xiaofan, Mankai Ju, Xinyue Dai, Quanrui Wu, Zan Zhou, Xiaomin Wang, Jiaojiao Yu, Hu Zhou, Renchi Yang, Lei Zhang

Blood (2022) 140 (Supplement 1): 8474–8475.

https://doi.org/10.1182/blood-2022-159948

Published: 2022

Journal Articles

Factor VII Deficiency in China: The Genotype-Phenotype Analysis and Current Status of Management

Qu Cuiyun, Wei Liu, Lingling Chen, Lei Zhang, Feng Xue, Renchi Yang

Blood (2022) 140 (Supplement 1): 5629.

https://doi.org/10.1182/blood-2022-158661

Published: 2022

Journal Articles

Eltrombopag Combining Rituximab Versus Eltrombopag for Treatment of Adult Immune Thrombocytopenia: A Single Center, Retrospective Cohort Study

Xu Yanmei, Liu Xiaofan, Yunfei Chen, Feng Xue, Wei Liu, Rongfeng Fu, Ting Sun, Mankai Ju, Renchi Yang, Lei Zhang

Blood (2022) 140 (Supplement 1): 5565–5566.

https://doi.org/10.1182/blood-2022-168463

Published: 2022

Journal Articles

Pre-Existing Anti-FVIII Immunity Alters Therapeutic Platelet-Targeted FVIII Engraftment in the System Preconditioned with Busulfan Alone through Cytotoxic CD8 T Cells

Weiqing Jing, Christina Baumgartner, Feng Xue, Jocelyn A. Schroeder, Qizhen Shi

Blood (2021) 138 (Supplement 1): 444.

https://doi.org/10.1182/blood-2021-153722

Published: 2021

Journal Articles

Extended Half-Life of the Double-Chain Recombinant Factor VIII-Fc Fusion Protein (FRSW107) in Hemophilia a Patients

Feng Xue, MD, Jing Sun, MD, Yun Chen, MD, Xinsheng Zhang, MD, Haiyan Sun, MD, Yali Wang, PhD, Renchi Yang, MD

Blood (2019) 134 (Supplement_1): 4932.

https://doi.org/10.1182/blood-2019-128600

Published: 2019

Journal Articles

Two Novel Knock-in and Knock-out of Setd2 Alleles Cooperate with Mll-Af9 Knock-in Allele to Accelerate Leukemia Development

Yunzhu Dong, Yoshihiro Hayashi, MD PhD, Xiaomei Yan, MD PhD, Feng Xue, PhD, Wei Chen, PhD, Gang Huang, PhD

Blood (2015) 126 (23): 555.

https://doi.org/10.1182/blood.V126.23.555.555

Published: 2015

Journal Articles

Lower Dosages of Intravenous Immunoglobulin (IVIg) in Treating Immune Thrombocytopenia with Long-Term Follow-up of Three Years

Zeping Zhou, Sr., MDPhD, Zhuoqing Qiao, MD, Huiyuan Li, PhD, Xian Zhang, PhD, Feng Xue, MDPhD, Renchi Yang, MDPhD

Blood (2015) 126 (23): 3480.

https://doi.org/10.1182/blood.V126.23.3480.3480

Published: 2015

NARROW

CM313, a Novel Anti-CD38 Antibody, As a Potential Treatment for Primary Immune Thrombocytopenia: A Phase II Trial

Emicizumab Prophylaxis for the Treatment of Chinese Hemophilia A Patients in the Real World: A Multi-Center Retrospective Analysis

Efficacy and Safety of Human Umbilical Cord-Derived Mesenchymal Stem Cells in the Treatment of Immune Thrombocytopenia: A Prospective, Single Centre, Single Arm, Phase I Trial

Pharmacokinetics, Safety and Preliminary Efficacy of Multiple Doses of Pegylated Recombinant Human Coagulation Factor VIII-Fc Fusion Protein (FRSW117) in Previously Treated Adult and Adolescent Subjects with Severe Hemophilia a: Results from an Open-Label, Multicenter, Phase 2 Study

Factor XI Deficiency in Chinese Patients: Results from a Nationwide Multicenter Retrospective Study

Acquired Hemophilia a: A Single-Center Study of 165 Patients

A Single-Center Study of Patients with Isolated Acquired Clotting Factor Deficiency: Clinical Features, Treatments, and Prognosis

Single-Dose Rituximab Plus Glucocorticoid Versus Cyclophosphamide Plus Glucocorticoid in Patients with Newly Diagnosed Acquired Hemophilia a: A Multicenter, Open-Label, Randomized Clinical Trial

A Single-Center Study of Patients with Isolated Acquired Clotting Factors Deficiency: Clinical Features, Treatments and Prognosis

Multi-Omics Analysis of Human Mesenchymal Stem Cell Guides Perinatal MSC Based Cellular Therapy for Splenectomy-Nonresponsive Refractory Immune Thrombocytopenia: A Phase I Clinical Trial

Predictive Factors of Relapse for Primary Immune Thrombocytopenia in Adults: A Single-Center Retrospective Cohort Analysis

Pharmacokinetics, Efficacy and Safety Evaluation of FRSW107 in Previously Treated Hemophilia a Patients: A Multicentre, Open-Label, Non-Randomized Phase III Study

AAV8 Gene Therapy for Hemophilia A Patients from China

Factor X Activator for Hemophilia Patients with Inhibitors: A Phase 1, First-in-Human, Multi-Center, and Open-Label Trial

Factor VII Deficiency in China: The Genotype-Phenotype Analysis and Current Status of Management

Eltrombopag Combining Rituximab Versus Eltrombopag for Treatment of Adult Immune Thrombocytopenia: A Single Center, Retrospective Cohort Study

Pre-Existing Anti-FVIII Immunity Alters Therapeutic Platelet-Targeted FVIII Engraftment in the System Preconditioned with Busulfan Alone through Cytotoxic CD8 T Cells

Extended Half-Life of the Double-Chain Recombinant Factor VIII-Fc Fusion Protein (FRSW107) in Hemophilia a Patients

Two Novel Knock-in and Knock-out of Setd2 Alleles Cooperate with Mll-Af9 Knock-in Allele to Accelerate Leukemia Development

Lower Dosages of Intravenous Immunoglobulin (IVIg) in Treating Immune Thrombocytopenia with Long-Term Follow-up of Three Years

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only